AbbVie Inc.

ABBV.BA·Buenos Aires·Healthcare
Compare
51,650.00+2,490.00 (+5.07%)today
At close: Nov 20, 5:52 PM ART · May be delayed up to 20 min · ARS

Prices may be delayed up to 20 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.

Key statistics

Previous close49,160.00
Open49,520.00
Day range49,520.0052,275.00
52-week range29,100.0052,275.00
Off day high−1.20%
Off 52-week high−1.20%
Volume1.57K
Avg. volume (3M)1.47K
Market cap91.30T
EPS (TTM)8,440.30
Forward P/E—
P/E ratio (TTM)6.12
Dividend yield2.31% (1,134.94)
Beta (5Y)0.19
Shares outstanding1.77B
Short interest—
Earnings date—
Analyst target—
Profit margin15.67%

Against its peers

Compare in full ›
ABBV.BA BMY 0QYQ.IL PFE BIIB ABVC
Market cap 91.30T 120.19B 209.33B 156.18B 36.89B 23.37M
P/E (TTM) 6.1 13.0 38.6 39.1 108.0 —
Forward P/E — 8.8 — 9.3 15.4 -2.0
Price/book -13.0 5.1 9.9 1.8 1.9 1.7
Dividend yield 2.31% 4.29% 3.81% 6.28% — —
1-year change +38.07% +23.12% +35.35% +8.64% +41.15% −67.29%
Today +5.07% +0.79% +0.60% −0.51% +1.00% −1.56%

The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.

Latest news

All ABBV.BA news ›
The Globe and Mail·Positive

AbbVie Advances ABBV-2294 Study for Rare Systemic Sclerosis

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer. Tipranks - Thu Nov 19, 10:35AM CST Abbvie (ABBV) announced an…

TIKR.com·Positive

AbbVie Is Up 27% in a Year. Barclays Sees Another 14%

Key Takeaways Barclays raised its AbbVie price target to $335 from $325 on Nov. 16 and kept its Overweight rating, after a run that has the stock up 27% in a year. AbbVie’s third quarter backed the bulls: revenue rose 10.3%, Skyrizi and…

TIKR.com·Positive

AbbVie Is Near Its High. Piper Sandler Sees Another 23%

Key Takeaways Piper Sandler raised its AbbVie price target to $349 from $303 and kept its Overweight rating, 23% above the Nov. 19 close of $283.54. Piper argues AbbVie deserves a higher multiple, partly on early data for Skyrizi…

European Medical Journal·Positive

AbbVie makes Formula 1 debut with McLaren

Therapy Area Allergy & Immunology Cardiology Dermatology Diabetes Flagship Journal Gastroenterology General Healthcare Hematology Hepatology Innovations Interventional Cardiology Microbiology & Infectious Diseases Nephrology Neurology…

From the 4Search news index, newest first.

In the news

215mentions in 30 days
182with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use. How to use Finance